What is Conmed Corp's earnings per share (EPS)?

Conmed Corp (CNMD) reported diluted earnings per share of $1.51 for fiscal year 2025. This represents a -64.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Conmed Corp Financials

CNMD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Conmed Corp (CNMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 47/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Conmed Corp has an operating margin of 7.5%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 39/100, indicating healthy but not exceptional operating efficiency. This is down from 15.3% the prior year.

Growth

Conmed Corp's revenue grew 5.2% year-over-year to $1.4B, a solid pace of expansion. This earns a growth score of 42/100.

Leverage

Conmed Corp carries a low D/E ratio of 0.81, meaning only $0.81 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Conmed Corp's current ratio of 2.14 indicates adequate short-term liquidity, earning a score of 39/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Conmed Corp has a free cash flow margin of 11.0%, earning a moderate score of 52/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Conmed Corp generates a 4.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 21/100. This is down from 13.8% the prior year.

Altman Z-Score Distress

1.77

Conmed Corp scores 1.77, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

6/9

Conmed Corp passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.63x

For every $1 of reported earnings, Conmed Corp generates $3.63 in operating cash flow ($170.7M OCF vs $47.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.3x

Conmed Corp earns $3.3 in operating income for every $1 of interest expense ($102.6M vs $31.1M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4B

YoY+5.2%

5Y CAGR+9.8%

10Y CAGR+6.7%

Conmed Corp generated $1.4B in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.

EBITDA

$155.3M

YoY-38.4%

5Y CAGR+9.5%

10Y CAGR+6.5%

Conmed Corp's EBITDA was $155.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.4% from the prior year.

Net Income

$47.1M

YoY-64.5%

5Y CAGR+37.7%

10Y CAGR+4.4%

Conmed Corp reported $47.1M in net income in fiscal year 2025. This represents a decrease of 64.5% from the prior year.

EPS (Diluted)

$1.51

YoY-64.5%

5Y CAGR+36.4%

10Y CAGR+3.3%

Conmed Corp earned $1.51 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$150.9M

YoY-2.0%

5Y CAGR+24.0%

10Y CAGR+15.4%

Conmed Corp generated $150.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 2.0% from the prior year.

Cash & Debt

$40.8M

YoY+66.9%

5Y CAGR+8.3%

10Y CAGR-5.6%

Conmed Corp held $40.8M in cash against $834.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.60

YoY-25.0%

5Y CAGR-5.6%

10Y CAGR-2.8%

Conmed Corp paid $0.60 per share in dividends in fiscal year 2025. This represents a decrease of 25.0% from the prior year.

Shares Outstanding

31M

YoY-0.2%

Conmed Corp had 31M shares outstanding in fiscal year 2025. This represents a decrease of 0.2% from the prior year.

Margins & Returns

Gross Margin

54.6%

YoY-1.5pp

5Y CAGR+1.2pp

10Y CAGR+1.5pp

Conmed Corp's gross margin was 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.

Operating Margin

7.5%

YoY-7.9pp

5Y CAGR+2.1pp

10Y CAGR+0.3pp

Conmed Corp's operating margin was 7.5% in fiscal year 2025, reflecting core business profitability. This is down 7.9 percentage points from the prior year.

Net Margin

3.4%

YoY-6.7pp

5Y CAGR+2.3pp

10Y CAGR-0.8pp

Conmed Corp's net profit margin was 3.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6.7 percentage points from the prior year.

Return on Equity

4.5%

YoY-9.2pp

5Y CAGR+3.2pp

10Y CAGR-0.7pp

Conmed Corp's ROE was 4.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$55.9M

YoY+2.7%

5Y CAGR+6.7%

10Y CAGR+7.4%

Conmed Corp invested $55.9M in research and development in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$19.8M

YoY+51.4%

5Y CAGR+8.8%

10Y CAGR+2.8%

Conmed Corp invested $19.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 51.4% from the prior year.

CNMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.4B+5.2%	$1.3B+5.0%	$1.2B+19.1%	$1.0B+3.4%	$1.0B+17.2%	$862.5M
Cost of Revenue	$624.2M+8.8%	$574.0M+1.0%	$568.5M+19.9%	$474.2M+7.1%	$442.6M+10.1%	$402.2M
Gross Profit	$750.5M+2.4%	$733.0M+8.4%	$676.2M+18.4%	$571.2M+0.6%	$568.0M+23.4%	$460.3M
R&D Expenses	$55.9M+2.7%	$54.4M+3.5%	$52.6M+11.6%	$47.2M+8.2%	$43.6M+7.6%	$40.5M
SG&A Expenses	$592.0M+23.8%	$478.3M-4.9%	$503.0M+10.8%	$454.0M+9.5%	$414.8M+11.0%	$373.8M
Operating Income	$102.6M-48.8%	$200.3M+66.1%	$120.6M+72.2%	$70.1M-36.2%	$109.7M+138.5%	$46.0M
Interest Expense	$31.1M-16.7%	$37.3M-6.2%	$39.8M+37.6%	$28.9M-18.5%	$35.5M-19.4%	$44.1M
Income Tax	$24.1M-21.4%	$30.6M+87.0%	$16.4M+68.4%	$9.7M-8.0%	$10.6M+233.5%	-$7.9M
Net Income	$47.1M-64.5%	$132.4M+105.4%	$64.5M+180.0%	-$80.6M-228.8%	$62.5M+557.2%	$9.5M
EPS (Diluted)	$1.51-64.5%	$4.25+108.3%	$2.04+176.1%	$-2.68-238.1%	$1.94+506.2%	$0.32

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$373.2M+10.4%	$337.9M-1.3%	$342.3M+6.6%	$321.3M-7.1%	$345.9M+9.2%	$316.7M-4.6%	$332.1M+6.3%	$312.3M
Cost of Revenue	$154.9M-9.8%	$171.8M+11.5%	$154.0M+7.3%	$143.5M-2.8%	$147.6M+7.2%	$137.7M-7.2%	$148.4M+5.7%	$140.3M
Gross Profit	$218.3M+31.4%	$166.1M-11.8%	$188.3M+5.9%	$177.8M-10.4%	$198.3M+10.8%	$179.0M-2.6%	$183.7M+6.8%	$172.0M
R&D Expenses	$14.9M+7.2%	$13.9M-1.7%	$14.1M+9.2%	$12.9M-1.7%	$13.2M-2.8%	$13.6M-3.8%	$14.1M+3.7%	$13.6M
SG&A Expenses	$166.8M+18.8%	$140.3M+3.2%	$136.0M-8.6%	$148.8M+12.2%	$132.7M+33.0%	$99.7M-18.6%	$122.5M-0.7%	$123.4M
Operating Income	$36.6M+208.3%	$11.9M-68.9%	$38.2M+139.1%	$16.0M-69.6%	$52.5M-20.1%	$65.7M+39.5%	$47.1M+34.5%	$35.0M
Interest Expense	$7.4M-3.1%	$7.6M-2.8%	$7.8M-5.6%	$8.3M-6.5%	$8.9M-4.3%	$9.3M-3.6%	$9.6M0.0%	$9.6M
Income Tax	$12.5M+785.0%	$1.4M-83.4%	$8.5M+419.4%	$1.6M-83.5%	$9.9M+32.3%	$7.5M-0.9%	$7.5M+32.0%	$5.7M
Net Income	$16.7M+485.5%	$2.9M-86.7%	$21.4M+254.9%	$6.0M-82.1%	$33.8M-31.1%	$49.0M+63.4%	$30.0M+52.1%	$19.7M
EPS (Diluted)	N/A	$0.09-87.0%	$0.69+263.2%	$0.19	N/A	$1.57+63.5%	$0.96+52.4%	$0.63

CNMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.3B+0.8%	$2.3B+0.3%	$2.3B+0.1%	$2.3B+30.1%	$1.8B+0.8%	$1.8B
Current Assets	$672.9M+5.1%	$640.0M+4.0%	$615.6M+5.9%	$581.2M+26.3%	$460.1M+10.4%	$416.7M
Cash & Equivalents	$40.8M+66.9%	$24.5M+0.7%	$24.3M-16.1%	$28.9M+38.8%	$20.8M-23.8%	$27.4M
Inventory	$355.5M+2.5%	$346.7M+8.9%	$318.3M-4.2%	$332.3M+43.5%	$231.6M+18.9%	$194.9M
Accounts Receivable	$247.8M+4.2%	$237.7M-1.9%	$242.3M+26.6%	$191.3M+4.1%	$183.9M+3.8%	$177.2M
Goodwill	$807.0M+0.2%	$805.4M-0.2%	$806.8M-1.1%	$815.4M+32.0%	$617.5M-0.1%	$618.4M
Total Liabilities	$1.3B-3.8%	$1.3B-8.3%	$1.5B-5.6%	$1.6B+58.3%	$980.6M-6.0%	$1.0B
Current Liabilities	$315.0M+13.3%	$278.1M-10.5%	$310.7M+4.8%	$296.6M+50.8%	$196.6M+3.4%	$190.2M
Long-Term Debt	$834.2M-7.8%	$905.1M-7.0%	$973.1M-1.2%	$985.1M+46.5%	$672.4M-8.5%	$735.2M
Total Equity	$1.0B+7.3%	$962.7M+15.4%	$834.2M+11.9%	$745.5M-5.1%	$785.4M+10.8%	$709.0M
Retained Earnings	$588.8M+5.1%	$560.3M+23.8%	$452.5M+9.7%	$412.6M-16.9%	$496.6M+8.6%	$457.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$2.3B+0.1%	$2.3B-0.3%	$2.3B+1.3%	$2.3B-0.4%	$2.3B-0.4%	$2.3B+1.3%	$2.3B-1.0%	$2.3B
Current Assets	$672.9M+1.6%	$662.2M+0.7%	$657.8M+2.9%	$639.0M-0.2%	$640.0M-0.2%	$641.0M+2.8%	$623.8M-1.9%	$635.7M
Cash & Equivalents	$40.8M+4.8%	$38.9M+14.7%	$33.9M-4.4%	$35.5M+45.1%	$24.5M-36.4%	$38.5M+33.2%	$28.9M-14.7%	$33.9M
Inventory	$355.5M-2.4%	$364.4M+0.6%	$362.3M+2.1%	$354.7M+2.3%	$346.7M+1.2%	$342.6M+6.3%	$322.4M0.0%	$322.3M
Accounts Receivable	$247.8M+10.2%	$224.9M-3.9%	$234.1M+5.9%	$221.1M-7.0%	$237.7M+2.8%	$231.2M-3.3%	$239.2M-0.9%	$241.5M
Goodwill	$807.0M0.0%	$806.9M0.0%	$806.9M+0.2%	$805.7M0.0%	$805.4M-0.2%	$806.9M+0.1%	$806.2M0.0%	$806.3M
Total Liabilities	$1.3B-1.6%	$1.3B-0.9%	$1.3B+0.4%	$1.3B-1.8%	$1.3B-2.8%	$1.4B-1.5%	$1.4B-3.5%	$1.5B
Current Liabilities	$315.0M+0.1%	$314.7M+6.7%	$294.8M+4.1%	$283.1M+1.8%	$278.1M-1.5%	$282.3M+6.0%	$266.4M-8.6%	$291.4M
Long-Term Debt	$834.2M-2.2%	$853.0M-3.2%	$881.1M-1.2%	$891.4M-1.5%	$905.1M-3.7%	$940.1M-2.6%	$965.2M-2.5%	$990.1M
Total Equity	$1.0B+2.5%	$1.0B+0.5%	$1.0B+2.6%	$977.6M+1.6%	$962.7M+3.2%	$932.9M+5.8%	$881.8M+3.2%	$854.7M
Retained Earnings	$588.8M+2.9%	$572.0M-0.6%	$575.4M+2.7%	$560.1M0.0%	$560.3M+5.2%	$532.7M+8.7%	$489.9M+5.1%	$466.1M

CNMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$170.7M+2.2%	$167.0M+33.2%	$125.3M+275.7%	$33.4M-70.1%	$111.8M+73.2%	$64.5M
Capital Expenditures	$19.8M+51.4%	$13.1M-31.3%	$19.0M-12.6%	$21.8M+46.5%	$14.9M+14.2%	$13.0M
Free Cash Flow	$150.9M-2.0%	$153.9M+44.7%	$106.3M+818.1%	$11.6M-88.1%	$96.9M+88.1%	$51.5M
Investing Cash Flow	-$21.0M-60.2%	-$13.1M+34.7%	-$20.0M+92.0%	-$249.5M-1578.5%	-$14.9M-9.0%	-$13.6M
Financing Cash Flow	-$135.8M+10.1%	-$151.0M-36.7%	-$110.4M-149.1%	$225.0M+321.6%	-$101.5M-95.1%	-$52.1M
Dividends Paid	$24.7M+0.4%	$24.7M+0.6%	$24.5M+2.3%	$24.0M+3.0%	$23.3M+1.9%	$22.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$46.3M-13.7%	$53.7M+84.3%	$29.1M-29.9%	$41.5M-4.2%	$43.3M-15.4%	$51.2M+18.2%	$43.3M+48.7%	$29.1M
Capital Expenditures	$5.1M-1.5%	$5.2M-9.5%	$5.7M+51.6%	$3.8M-6.5%	$4.0M+18.2%	$3.4M-4.8%	$3.6M+76.4%	$2.0M
Free Cash Flow	$41.2M-15.0%	$48.5M+107.2%	$23.4M-38.0%	$37.8M-3.9%	$39.3M-17.8%	$47.8M+20.3%	$39.7M+46.6%	$27.1M
Investing Cash Flow	-$7.1M-37.1%	-$5.2M+9.5%	-$5.7M-95.6%	-$2.9M+27.5%	-$4.0M-18.2%	-$3.4M+4.8%	-$3.6M-76.4%	-$2.0M
Financing Cash Flow	-$37.4M+14.1%	-$43.5M-64.1%	-$26.5M+6.6%	-$28.4M+44.4%	-$51.1M-31.5%	-$38.8M+11.9%	-$44.1M-159.1%	-$17.0M
Dividends Paid	$6.2M0.0%	$6.2M0.0%	$6.2M+0.1%	$6.2M0.0%	$6.2M+0.2%	$6.2M+0.1%	$6.2M+0.1%	$6.2M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	54.6%-1.5pp	56.1%+1.7pp	54.3%-0.3pp	54.6%-1.6pp	56.2%+2.8pp	53.4%
Operating Margin	7.5%-7.9pp	15.3%+5.6pp	9.7%+3.0pp	6.7%-4.2pp	10.9%+5.5pp	5.3%
Net Margin	3.4%-6.7pp	10.1%+5.0pp	5.2%+12.9pp	-7.7%-13.9pp	6.2%+5.1pp	1.1%
Return on Equity	4.5%-9.2pp	13.8%+6.0pp	7.7%+18.5pp	-10.8%-18.8pp	8.0%+6.6pp	1.3%
Return on Assets	2.0%-3.7pp	5.7%+2.9pp	2.8%+6.3pp	-3.5%-7.1pp	3.5%+3.0pp	0.5%
Current Ratio	2.14-0.2	2.30+0.3	1.98+0.0	1.96-0.4	2.34+0.1	2.19
Debt-to-Equity	0.81-0.1	0.94-0.2	1.17-0.2	1.32+0.5	0.86-0.2	1.04
FCF Margin	11.0%-0.8pp	11.8%+3.2pp	8.5%+7.4pp	1.1%-8.5pp	9.6%+3.6pp	6.0%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	58.5%+9.3pp	49.2%-5.9pp	55.0%-0.3pp	55.3%-2.0pp	57.3%+0.8pp	56.5%+1.2pp	55.3%+0.3pp	55.1%
Operating Margin	9.8%+6.3pp	3.5%-7.6pp	11.2%+6.2pp	5.0%-10.2pp	15.2%-5.6pp	20.8%+6.6pp	14.2%+3.0pp	11.2%
Net Margin	4.5%+3.6pp	0.9%-5.4pp	6.3%+4.4pp	1.9%-7.9pp	9.8%-5.7pp	15.5%+6.4pp	9.0%+2.7pp	6.3%
Return on Equity	1.6%+1.3pp	0.3%-1.9pp	2.1%+1.5pp	0.6%-2.9pp	3.5%-1.7pp	5.3%+1.8pp	3.4%+1.1pp	2.3%
Return on Assets	0.7%+0.6pp	0.1%-0.8pp	0.9%+0.7pp	0.3%-1.2pp	1.5%-0.7pp	2.1%+0.8pp	1.3%+0.5pp	0.9%
Current Ratio	2.14+0.0	2.10-0.1	2.23-0.0	2.26-0.0	2.30+0.0	2.27-0.1	2.34+0.2	2.18
Debt-to-Equity	0.81-0.0	0.85-0.0	0.88-0.0	0.91-0.0	0.94-0.1	1.01-0.1	1.09-0.1	1.16
FCF Margin	11.1%-3.3pp	14.3%+7.5pp	6.8%-4.9pp	11.8%+0.4pp	11.4%-3.7pp	15.1%+3.1pp	12.0%+3.3pp	8.7%

Similar Companies

Enovis Corp ENOV

$1.3B

Ufp Technologies UFPT

$1.5B

Artivion, Inc. AORT

$1.6B

Novocure NVCR

$1.2B

SS Innovations SSII

$1.0B

Frequently Asked Questions

What is Conmed Corp's annual revenue?

Conmed Corp (CNMD) reported $1.4B in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Conmed Corp's revenue growing?

Conmed Corp (CNMD) revenue grew by 5.2% year-over-year, from $1.3B to $1.4B in fiscal year 2025.

Is Conmed Corp profitable?

Yes, Conmed Corp (CNMD) reported a net income of $47.1M in fiscal year 2025, with a net profit margin of 3.4%.

What is Conmed Corp's EBITDA?

Conmed Corp (CNMD) had EBITDA of $155.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Conmed Corp have?

As of fiscal year 2025, Conmed Corp (CNMD) had $40.8M in cash and equivalents against $834.2M in long-term debt.

What is Conmed Corp's gross margin?

Conmed Corp (CNMD) had a gross margin of 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Conmed Corp's operating margin?

Conmed Corp (CNMD) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Conmed Corp's net profit margin?

Conmed Corp (CNMD) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Conmed Corp pay dividends?

Yes, Conmed Corp (CNMD) paid $0.60 per share in dividends during fiscal year 2025.

What is Conmed Corp's return on equity (ROE)?

Conmed Corp (CNMD) has a return on equity of 4.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Conmed Corp's free cash flow?

Conmed Corp (CNMD) generated $150.9M in free cash flow during fiscal year 2025. This represents a -2.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Conmed Corp's operating cash flow?

Conmed Corp (CNMD) generated $170.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Conmed Corp's total assets?

Conmed Corp (CNMD) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Conmed Corp's capital expenditures?

Conmed Corp (CNMD) invested $19.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Conmed Corp spend on research and development?

Conmed Corp (CNMD) invested $55.9M in research and development during fiscal year 2025.

How many shares does Conmed Corp have outstanding?

Conmed Corp (CNMD) had 31M shares outstanding as of fiscal year 2025.

What is Conmed Corp's current ratio?

Conmed Corp (CNMD) had a current ratio of 2.14 as of fiscal year 2025, which is generally considered healthy.

What is Conmed Corp's debt-to-equity ratio?

Conmed Corp (CNMD) had a debt-to-equity ratio of 0.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Conmed Corp's return on assets (ROA)?

Conmed Corp (CNMD) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Conmed Corp's Altman Z-Score?

Conmed Corp (CNMD) has an Altman Z-Score of 1.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Conmed Corp's Piotroski F-Score?

Conmed Corp (CNMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Conmed Corp's earnings high quality?

Conmed Corp (CNMD) has an earnings quality ratio of 3.63x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Conmed Corp cover its interest payments?

Conmed Corp (CNMD) has an interest coverage ratio of 3.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Conmed Corp?

Conmed Corp (CNMD) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.